Fact CheckerSign in

NCT04805021Completed

Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells

Source: ClinicalTrials.gov · Last updated 24 Sept 2026

Brief summary (registry, in English)

Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused by the sometimes drastic decrease in the level of circulating factor VIII. This pathology occurs overwhelmingly in elderly subjects or, more rarely, in young women, during the postpartum period. It appears idiopathic in 50% of cases and associated, for the other cases, with underlying pathologies such as autoimmune pathologies (rheumatoid arthritis and bullous pemphigoid in particular) and neoplasias, or with a particular circumstance represented by the post -partum. The association between this autoimmune pathology and its association with pathologies of the same type or with circumstances involving the immune system, suggests that common mechanisms could favor its emergence. This study therefore proposes to study lymphocyte populations and subpopulations as well as Myeloid-Derived Suppressor Cells and the cytokine profile, which are abnormal in a large part of autoimmune pathologies.

Status (registry)
Completed
Study type
Observational
Enrollment
36 (actual)
First submitted
16 Mar 2021
Start date
30 Nov 2021
Primary completion date
25 Mar 2024
Lead sponsor
Nantes University Hospital
Diseases
Haemophilia
NCT number
NCT04805021

What you commit to

  • Study type: Observational
  • Participants enrolled: 36
  • From 30 Nov 2021 to the primary completion date, 25 Mar 2024
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Treatment with corticosteroids in the 7 days preceding inclusion or any other immunomodulatory or immunosuppressive treatment in the 4 weeks preceding inclusion.

Other

  • For the 4 groups:
  • Minor patient, under guardianship or curatorship.
  • Pregnant and lactating women.
  • Blood transfusion less than 7 days old.

Who the study is looking for

  • Patient population with acquired hemophilia A:
    • Adult patients with a diagnosis of acquired hemophilia A and with a social security system. Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
    • Obtaining signed and written informed consent for biocollection consent.
  • Population of Patients with constitutional hemophilia A:
    • Adult patients over 50 years of age with severe or moderate constitutional hemophilia A, with no history of autoimmune disease, and with a social security system.
    • Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
    • Obtaining signed and written informed consent for biocollection consent.
  • Population of control subjects:
    • Adult patients, over the age of 60, without a coagulation abnormality, with no history of autoimmune disease, and with a social security system.
    • Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
    • Obtaining signed and written informed consent for biocollection consent.
  • Patient population with inflammatory pathology:
    • Adult patients over the age of 50 with an inflammatory pathology likely to be associated with acquired hemophilia A, and with a social security system.
    • Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
    • Obtaining signed and written informed consent for biocollection consent.

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CHU de Nantes
Coordinator of this site? Confirm its status
NantesFranceUnknown status
CH de Saint Nazaire
Coordinator of this site? Confirm its status
Saint-NazaireFranceUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.